DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Earnings: Here's What Analysts Think

DiaSorin S.p.A. (BIT:DIA) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to €86.20 in the week after its latest interim results. It was an okay report, and revenues came in at €619m, approximately in line with analyst estimates leading up to the results announcement. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the most recent consensus for DiaSorin from twelve analysts is for revenues of €1.24b in 2025. If met, it would imply an okay 2.2% increase on its revenue over the past 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of €1.24b and earnings per share (EPS) of €3.81 in 2025. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.

See our latest analysis for DiaSorin

There's been no real change to the consensus price target of €107, with DiaSorin seemingly executing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on DiaSorin, with the most bullish analyst valuing it at €122 and the most bearish at €82.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 4.5% growth on an annualised basis. That is in line with its 5.5% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 6.6% annually. So although DiaSorin is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at €107, with the latest estimates not enough to have an impact on their price targets.

At least one of DiaSorin's twelve analysts has provided estimates out to 2027, which can be seen for free on our platform here.

It might also be worth considering whether DiaSorin's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.